Gordon B. Mills, MD, PhD

home / authors / gordon-b-mills-md-phd

Articles

Dr. Mills Gives Examples of Unexpected Drug Responses

Dr. Mills Gives Examples of Unexpected Drug Responses

Gordon B. Mills, MD, PhD
October 28th 2011

Dr. Gordon Mills from MD Anderson Cancer Center Gives Examples of Unexpected Therapy Responses

Read More

Dr. Mills Discusses the Field of Targeted Therapeutics

Dr. Mills Discusses the Field of Targeted Therapeutics

Gordon B. Mills, MD, PhD
October 18th 2011

Dr. Gordon B. Mills from the University of Texas MD Anderson Cancer Center Discusses the Field of Targeted Therapeutics

Read More

Dr. Mills on the Development of Combination Therapies

Dr. Mills on the Development of Combination Therapies

Gordon B. Mills, MD, PhD
October 7th 2011

Dr. Gordon B. Mills from MD Anderson Cancer Center Discusses the Development of Combination Therapies

Read More

Dr. Mills Explains the Vulnerability of Cancer Cells

Dr. Mills Explains the Vulnerability of Cancer Cells

Gordon B. Mills, MD, PhD
October 3rd 2011

Dr. Gordon Mills from MD Anderson Cancer Center Explains the Vulnerability of Cancer Cells

Read More

Dr. Mills on the Shifts Towards Personalized Medicine

Dr. Mills on the Shifts Towards Personalized Medicine

Gordon B. Mills, MD, PhD
September 29th 2011

Dr. Gordon B. Mills from MD Anderson Cancer Center Discusses Shifts Towards Personalized Medicine

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need